Integra Therapeutics to present ex vivo and in vivo data for its FiCAT gene writing platform at Advanced Therapies Europe congress
Integra Therapeutics will present positive data from ex vivo and in vivo preclinical studies that demonstrates the potential of its FiCAT gene writing platform for developing advanced therapies in the field of paediatric hepatology at the Advanced Therapies Europe congress, taking place in Estoril (Portugal) from 5 to 7 September. Dr Avencia Sánchez-Mejías, CEO and […]
Integra Therapeutics CEO Avencia Sánchez-Mejías to speak at Global Synthetic Biology Conference
Integra Therapeutics CEO, Dr Avencia Sánchez-Mejías, will be a featured speaker at the Global Synthetic Biology Conference from May 23 to 25 in Oakland, California. Hosted by SynBioBeta, this is the biggest event for business and investment in the field of synthetic biology, showcasing the cutting-edge industrial developments that are transforming how we fuel, heal […]
Integra Therapeutics presents video ‘New FiCAT gene writing platform to cure diseases’
On 25 April, to celebrate DNA Day 2023, Integra Therapeutics launched a video explaining the new FiCAT gene writing platform developed by its scientific team. The video also explains the advances this entails in achieving more efficient and precise advanced therapies to cure patients through programmable DNA insertion to their genome. This year, DNA Day […]
Integra Therapeutics awarded Neotec grant to advance FiCAT platform in vivo deployment for gene therapy
Integra Therapeutics has been awarded a €335,000 non-refundable grant through the Spanish Ministry of Science and Innovation Neotec programme, managed by the Centre for the Development of Industrial Technology (CDTI). Neotec is a highly competitive programme that aims to foster technology and innovation for the development of companies based in Spain. In the 2022 call, […]
Integra Therapeutics, UPF and Josep Carreras Leukaemia Research Institute to develop CAR-T therapy for T-ALL
The public-private consortium made up of Integra Therapeutics, Pompeu Fabra University (UPF) and the Josep Carreras Leukaemia Research Institute (IJC) has received a grant of €1,230,732 from the Spanish State Research Agency (AEI) to develop new genetic engineering technology for a CAR-T therapy to treat T-cell acute lymphoblastic leukaemia (T-ALL). The funds are a competitive […]
Marc Güell wins the Spanish National Research Award for Young People 2022
Dr Marc Güell has received the Ángela Ruiz Robles 2022 National Research Award for Young People, in the field of technology transfer, awarded by the Ministry of Science and Innovation of Spain. He was recognised for his contributions in harnessing synthetic biology to generate new basic principles of molecular biology for the design of biological […]
Integra Therapeutics and Caszyme receive €1-million Eurostars grant
Integra Therapeutics has been awarded €1-million grant from Eurostars, the largest funding programme of the European Commission that supports innovative SMEs in developing collaborative transnational projects geared towards the market. The company applied for the call as part of a consortium with Caszyme, a Lithuanian company that specialises in CRISPR technology and molecular tools development […]
Integra Therapeutics chosen one of the ten most disruptive companies by the Government of Catalonia
Integra Therapeutics is now one of the Catalonia Exponential Leaders, an initiative promoted by ACCIÓ (Government of Catalonia) to identify and raise awareness of business projects that can adapt, transform and have a global impact on the most significant economic and social areas for the future. The distinction has announced today at the 2022 Exponential […]
Integra Therapeutics receives Catalan Society of Biology Award 2022
Integra Therapeutics has received the Catalan Society of Biology (SCB) Award for best innovative start-up of 2022 for developing the next-generation of gene writing tools for therapeutic purposes in the field of life sciences. The SCB Board of Directors recognised Integra Therapeutics’ innovative technology, the benefit to society and the team‘s ability to bring the […]
Marc Güell, new member of Young Academy of Spain
Dr Marc Güell, co-founder of Integra Therapeutics and principal investigator of the Translational Synthetic Biology Laboratory at Pompeu Fabra University (UPF), has been made a member of the Young Academy of Spain (AJE) after a selection process with 87 candidates. He will belong to the AJE for five years. This makes Dr Güell an Academic […]
